Nemaura Medical Inc. Stock

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 11:12:20 2024-04-29 EDT 5-day change 1st Jan Change
0.0538 USD -0.70% Intraday chart for Nemaura Medical Inc. -25.28% -75.43%
Sales 2024 * 200K 273K Sales 2025 * 1.4M 1.91M Capitalization 2.19M 2.98M
Net income 2024 * -9M -12.28M Net income 2025 * -12M -16.38M EV / Sales 2024 * 10.9 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.56 x
P/E ratio 2024 *
-0.17 x
P/E ratio 2025 *
-0.12 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.70%
1 week-25.28%
Current month-39.55%
1 month-40.16%
3 months-32.75%
6 months-79.52%
Current year-75.43%
More quotes
1 week
0.05
Extreme 0.0521
0.08
1 month
0.05
Extreme 0.0521
0.10
Current year
0.05
Extreme 0.0521
0.21
1 year
0.05
Extreme 0.0521
1.25
3 years
0.05
Extreme 0.0521
17.40
5 years
0.05
Extreme 0.0521
17.40
10 years
0.05
Extreme 0.0521
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Chief Executive Officer 50 13-12-23
More insiders
Date Price Change Volume
24-04-29 0.0538 -0.70% 23 812
24-04-26 0.0542 -4.39% 10,833
24-04-25 0.0567 -12.78% 82,647
24-04-24 0.065 +8.33% 44,065
24-04-23 0.06 -16.67% 119,656

Delayed Quote OTC Markets, April 29, 2024 at 11:12 am

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0542 USD
Average target price
1.5 USD
Spread / Average Target
+2,667.53%
Consensus